Advances in insulin formulations continue to be an important aspect for diabetes management; however, there is a need to establish clinical safety and efficacy of these formulations. Presently, the increased availability of continuous glucose monitoring devices allows a more intricate analysis of clinical insulin action. This permits an assessment of new insulins which may help to achieve optimal glycemic control beyond HbA1c. Lilly and Docplexus have organized an interactive Webinar on 7th March 2019 at 12:30 pm .
In this Webinar session, Professor Glenn Matfin will discuss on the Updates And Advances In Rapid-Acting Insulin Therapy . The webinar will cover information on the bioequivalent and cost-effective alternatives for the existing rapid-acting human insulin analogue indicated to improve glycemic control in diabetic patients. We invite you to submit your questions which will be…
